No 340B Savings for Transgender Care Act

# Summary of HR 2197: No 340B Savings for Transgender Care Act **What the Bill Would Do** This bill would modify the 340B drug pricing program, a federal program that allows certain hospitals and health centers to purchase medications at discounted prices. Specifically, the bill would prohibit these organizations from using their 340B savings to pay for gender-affirming medical care and treatments for transgender individuals. Currently, covered entities can use their drug discount savings for any patient care purpose. **Who It Affects** The bill would impact hospitals, federally qualified health centers, and other healthcare organizations that participate in the 340B program. It would also restrict access to gender-affirming treatments for transgender patients who receive care at these facilities.

The bill does not prevent these organizations from offering such care—it only prevents them from using their 340B drug savings to fund it. **Current Status** HR 2197 was introduced in the 119th Congress by Rep. Dusty Johnson (R-SD) and is currently in committee. The bill has not yet been voted on by the full House of Representatives.